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Title: Brain microvasculature defects and Glut1-deficiency syndrome averted by early repletion of the  
Glucose Transporter-1 protein  
 
This manuscript investigates the therapeutic effects of temporal treatment of AAV9-constructs in the 
model mice of Glut1-deficiency syndrome. Glut1 repletion in neonates by using such a vector was 
found to improve motor performance, reverse low CSF gluocose, enable the normal development of 
the brain microvasculature and prevents microencephaly in Glut1-DS mice. This study demonstrated 
that insufficiency of Glut1 protein arrests normal neonatal cerebral angiogenesis, whereas timely 
AAV9-mediated repletion of the protein prevented the diminution of brain microvasculature and thus 
ameliorates the disease.  
There is no cure for Glut1-DS patients and the standard treatment so far is the ketogenic diet, which 
has been effective in treating seizures, but less effective in cognitive impairment or behavioral issues. 
Therefore it is promising that AAV9-mediated treatment could restore some of the brain functions and 
prevent the microencephaly which is one of the main symptoms of Glut1-DS. However, there are 
some major concerns about this study:  
The authors state that an AAV9-mediated viral repletion of Glut1 protein acts mainly through 
restoration of brain microvasculature. However, the evidences for a restoration of the angiogenesis 
are not either sufficient or convincing. Firstly, the vasculature parameters from three slices of 
thalamus per animal are not sufficient for a statement of angiogenesis for the whole brain. What about 
the capillaries in the other brain regions, such as cortex and hippocampus, which are the brain regions 
that related closely with motor and cognitive function? Secondly, the perfusion status of the capillaries 
in a whole brain, as well as in some specific brain regions, should be provided (like a perfusion-
weighted MRI study), to confirm a regaining of the capillary function. Thirdly, there is no direct causal 
link either between Glut1 protein and angiogenesis, or between the regained angiogenesis and the 
improved motor function. Lastly, since the in vitro study of functional evaluation of Glut1 constructs 
was done in patient fibroblasts, not in endothelial cells, this data may not support the function of Glut1 
expression via AAV9 constructs in endothelial cells of the capillaries in vivo. Generally, although the 
timely treatment of AAV9-Glut1 is effective, the results from this study do not fully support the 
statement that angiogenesis is the link between Glut1 repletion and improved brain function.  
Minor comments:  
1. The methods indicate two routes of virus delivery, systemic and intra-cerebral injection. However, it 
not been clarified which route has been used for each related experiment.  
2. Although one supplementary figure shows no difference between facial vein injection and ICV 
injection, in terms of blood/CSF glucose and body/brain weight. Due to BBB, usually the local brain 
injection should yield higher viral expression. Please also provide immunohistochemistry images if 
there is no difference in Glut1 expression between two injection routes.  
3. Seems like no fluorescence being conjugated in the viral construct, so it is very difficult to evaluate 
the viral expression level in the capillary endothelial cell as well as brain tissue. It would be more 
convincing to provide the immunostaining of Glut1 for all the quantification of the blood vessels.  
4. Seizures occur frequently to the Glut1-DS patients. Since the Glut1-DS model mice also have 
seizure activity as author states, experiments should be done to indicate how effective the treatment 
to reduce seizures.  
 Reviewer #2 (Remarks to the Author):  
 
In this work the authors explore the impact of reduced expression of the Glut-1 protein expression in 
brain development in genetically targeted mice. The analysis of mice with only one intact Glut-1 gene, 
and thus a 50% reduction of the protein levels in the microvasculature is a model of the human 
condition known as Glut1-deficiency syndrome (Glut1-DS). In humans, this condition disrupts normal 
brain function and cause a severe pedriatic defect in brain development. Glut-1-DS is considered as a 
very rare condition but novel estimates reveal that is might be more prevalent than previously 
thought. The results in this work show that Glut-1 deficiency in mice causes severe defects in brain 
development with arrested postnatal angiogenesis leading to a defect brain microvasculature, similar 
to the human condition. Attempts to restore Glut-1 levels in heterozygous Glut-1 mice using AAV9-
mediated gene transduction during early postnatal development resulted in restoration of 
angiogenesis and prevention of disease development. However, in older mice, the gene transduction 
had less beneficial effects and in adult mice no improvements were seen. Thus the authors identified a 
time window in which Glut-1 repletion in early symptomatic animals can restore the cerebral 
miscrovasculature and ameliorate the disease.  
 
General; This manuscript describes a set of carefully conducted experiments that addresses a 
medically import area, namely a treatment paradigm for the devastating consequences of glucose 
deficiency in the CNS. The results are clearly presented and the conclusions are supported by the 
experimental data. A number of important control experiments are also included. The manuscript is 
well written and easy to understand.  
 
Specific comments; I find it surprising that no effect on the integrity of the BBB can be observed since 
the brain parenchyma obviously suffers from an energy deficient state. The author use fluorescently 
labelled macromolecules to reach this conclusion. This is also in contrast to a previous finding in the 
fish. Have the authors tested tracers of lower molecular weights to more carefully address the BBB 
integrity and can that explain the differences to previous results?  
Secondly, can the authors explain why the are very significant differences in CSF glucose 
concentrations between the mutant mice, mutant mice + AAV transducer and wt, probably reflecting 
differential endothelial uptake of blood glucose, and the PET data presented in Fig. 5a. The 
discrepancy is quite huge and needs to be explained.  
 
 
Reviewer #3 (Remarks to the Author):  
 
The major findings presented in this manuscript entitled "Brain microvasculature defects and Glut1-
deficiency syndrome averted by early repletion of the  
Glucose Transporter-1 protein' by Tang, M et al are essentially as described in the title. Mice with a 
happloinsufficiency of the SLC2A1 gene express reduced levels of the Glut1 glucose transporter in the 
brain and other tissues. This condition results neuroglycopenia and hypocorrhachia that leads to 
seizures, delayed neural development, microcephaly and movement disorders. The authors 
demonstrate that infection of these mice with an aav9 virus expressing Glut1 can prevent/reverse 
these symptoms if introduced early in the course of neural development i.e. up to postnatal day 14 
but was ineffective when introduced in the 8-week adult mouse despite being able to promote 
increased CNS glucose uptake. They also describe the reduced cerebral microvascular development 
resulting from the happloinsufficiency, which is not novel as Dr. DiVivo and other colleagues (Winkler 
et al, 2015) had previously been shown this to be the case. However, in contrast to the previous 
study, the current study does not find any breakdown in the blood-brain barrier. Given that both 
studies apparently use the same mice, a more comprehensive discussion of these important 
differences should be provided.  
General Comments  
A major concern this reviewer has with this manuscript is the failure to recognize the significance of 
the other Glut1 protein (45 KDa) that resides in all glia, which in this mouse model is also reduced by 
50%. On Western blots of whole adult brain tissue it represents >65% of the total Glut1 protein 
(Vannucci, ref 47) that is detected and there is no indication as to whether in the repletion 
experiments, the Glut1 aav9 virus is repopulating the transporter deficient astrocytes. The blots as 
presented do not adequately resolve the proteins in the brain samples. The role of astrocytes in both 
neuronal development and neural homeostasis widely appreciated. Moreover, the growing belief that 
astrocytes are responsible for providing energy in the form of lactate for neuronal metabolism (see 
reviews by Magistretti). The loss of 50% of the Glut1 transporters would certainly compromise 
astrocytic and neuronal growth and would obviously lead to not only energy depletion and seizures but 
ultimately microcephaly. Astrocytes also play a crucial role in angiogenesis, which is compromised in 
these mice and is also not considered in the proposed figure 8. The authors proposed that the 
endothelial cell metabolism is compromised by the transporter deficiency. This would appear to be 
unlikely as circulating glucose levels are normal and the endothelial cells represent 2% of the brain 
and require only a very small % of the glucose that is transported into the brain for neuronal and glial 
metabolism. Compromised astrocytes and pericytes would be more likely to impair angiogenesis.  
Finally it seems obvious given the time table for neurogenesis in the mouse is essentially complete by 
4 weeks that adding back what would be a vital transporter for development 4 or 16 weeks after 
neurogenesis is completed would be without effect. A more comprehensive description of neural 
development would put the observations in context-i.e what is the time-table for the development of 
astrocytes, oligodendrocytes, neurons and endothelial cells.  
 
Specific Comments  
Results  
In Figure 3 the authors describe the infection of patient fibroblasts with the Glut1 aav9 construct. A 
couple of questions arise 1) why are there two forms of the transporter and do they really represent a 
45KDa and 55 KDa form of the transporter or is this an artifact of gel system. Running a microvessel 
sample as a control would address this question. 2) Do the control patient fibroblasts increase their 
transporter level if infected?  
There appears to be no distinction as to whether the virus was presented by icv or through the facial 
vein therefore it would appear that the virus has complete access to the CNS by either route. Can the 
authors confirm this and demonstrate incorporation of the viral Glut 1 into astrocytes.  
P10- not transgenic  
P12- 'prevents release into the circulation' needs clarification  
Discussion  
A discussion of the similarities and differences between the current paper and that of Winkler et al 
should be expanded.  
When considering the human patients it should be noted that under normal circumstances patients are 
less innately ketogenic than rodents.  
Angiogenisis is but one component in the neural dysfunction caused by a lack of Glut1-see general 
comments. This requires Fig 8 to be revised or scraped  
P16. As indicated above the haploinsufficiency is unlike to impede endothelial cell metabolism.  
P16 the increase in 45 KDa Glut1 concentration is 5 fold between day14 and 28 whereas the 55 kDa 
Glut1 is at most 2 fold over the same period (ref 47).  
Methods  
The resolution of 55 and 45 KDa could be significantly improved to resolve any differential contribution 





We were encouraged by the reviewer’s prompt acknowledgment of the lack of a truly effective treatment for Glut1-DS 
and his recognition of the significance of studies to develop an optimal therapy for the disease.  Accordingly, we wish to 
thank him for noting that “it is promising that AAV9-mediated treatment could restore some of the brain functions and 
prevent the microcephaly which is one of the main symptoms of Glut1-DS.” Yet he did raise several concerns most of 
which centered on a potential link we highlight between Glut1 deficiency and a poorly developed brain 
microvasculature. We have assiduously attempted to address this concern. Specific points in connection with this 
criticism and our responses to these follow below: 
1.   Comment: “The vasculature parameters from three slices of thalamus per animal are not sufficient for a 
statement of angiogenesis for the whole brain. What about the capillaries in the other brain regions, such as 
cortex and hippocampus, which are the brain regions that are related closely with motor and cognitive 
function?” 
Response: We fully agree with the reviewer’s comment and never meant to focus exclusively on the 
microvasculature of the thalamus. The results from this brain region were emphasized merely because the 
thalamus, as stated in the original text, was found to be particularly hypometabolic in previous studies 
conducted by our group.  Nevertheless, we ought to have included data from other brain regions and do so now. 
In particular, we examined the cortex (primary motor cortex and somatosensory cortex) as well as hippocampus 
(CA1, CA3 and dentate gyrus) noting a similar paucity of capillaries in the vehicle-treated Glut1-DS mutant. 
Importantly, the complexity of the microvasculature was restored following early repletion of AAV9-Glut1. This 
not only strengthens the results from the thalamus but also further attests to the link between Glut1 and the 
capillary network in the overall brain. The results are now included in the section titled, “Brain microvasculature 
defects in Glut1-DS model mice” – page 4 – and expanded upon in later sections as well as in Fig. 5. 
2.   Comment: “The perfusion status of the capillaries in a whole brain, as well as in some specific brain regions 
should be provided to confirm a regaining of capillary function.” 
Response: We address this point by resorting to a well-established in vivo imaging technique that exploits 2- 
photon microscopy and examines the brain microvasculature in live animals (McCaslin, A.F.H. et al, 2011, J Cereb 
Blood Flow Metab. 31:795-806 and references therein).  In essence then, the analysis is conducted on normally 
perfused capillaries rather than on fixed tissue.  As expected, we found fewer perfused capillaries in vehicle- 
treated mutants at all depths examined. In contrast, early treatment with AAV9-Glut1 restored the network to a 
wild-type state. The results now constitute Fig. 5c, e & f, Supplementary Video 1 and a relevant description in 
the main text (page 11). The new experiments focused on the brain cortex as a matter of necessity; 2-photon 
imaging allows one to examine cortical capillaries up to depths of ~700m, but unlike MRI studies one can do so 
with unparalleled clarity, visualizing the complexity and morphology of individual vessels. We do hope that 
when combined with our analysis of the various regions of the fixed (4% PFA) brain, the data satisfactorily 
convinces the reviewer of the link between Glut1 and the brain microvasculature. 
3.   Comment: “There is no direct causal link either between Glut1 protein and angiogenesis, or between the 
regained angiogenesis and the improved motor function.” 
Response: Although we agree that we failed, in the original manuscript, to conclusively establish a direct link 
between Glut1 and angiogenesis, we were not altogether dismissive of potential mechanisms connecting one 
with the other, speculating in the Discussion section on the possibility that reduced glycolytic flux in endothelial 
cells perturbs their ability to properly form blood vessels.  We expand on this angle in the revision (Fig. 3, 
Supplementary Fig. 4 and a new paragraph in the text – page 6), demonstrating that Glut1 deficient cells in 
culture do indeed exhibit evidence not only of reduced glycolysis but also of maximal respiration. Perturbations 
in glycolysis have been clearly shown by the Carmeliet group to inhibit capillary sprouting (Cruys, B. et al, 2015, 
Nat. Commun. 7: 12240; De Bock, K. et al, 2013, Cell, 154: 651-663).  It would not be a stretch to assume, given 
our new results, that low Glut1 reduces glycolytic flux and that this state conspires with an inability of the 
endothelial cell to attain maximal respiration, to hinder angiogenesis in Glut1-DS. Reduced glycolysis is clearly 
sufficient to impede angiogenesis according to De Bock et al. However, it may not be the exclusive mechanism 
linking Glut1 to defects of angiogenesis. In support of this claim, we also draw the reviewer’s attention to new 
data we have generated (Fig. 3) demonstrating a significant decline in levels of the angiogenesis effector Vegfr2 
in Glut1-DS endothelial cells (microvasculature). Knockdown of Vegfr2 in endothelial cells has been shown to 
affect their proliferation (Shalaby, F. et al, 1995, Nature, 376:62-66) and consequently, this molecule could 
function as a second mediator of poor angiogenesis in Glut1. While we are excited by these findings and believe 
they address, at least in part, the reviewer’s comment, we readily admit that revealing precise mechanisms will 
require a great deal more work. Teasing out the details of such mechanisms and the exact links between 
defective angiogenesis and motor abnormalities will involve painstaking examinations of the intricate circuitry of 
the brain. Such experiments are simply beyond the scope of this article which is mainly meant to highlight the 
future promise of gene replacement as a means to treat Glut1-DS. We do hope the reviewer agrees. 
4.   Comment: “Since the in vitro study of functional evaluation of Glut1 constructs was done in patient fibroblasts, 
not in endothelial cells, this data may not support the function of Glut1 expression via AAV9 constructs in 
endothelial cells of the capillaries in vivo.” 
Response: We appreciate the reviewer’s comment but gently remind him that while the initial functional 
evaluation was carried out in patient fibroblasts, subsequent analyses involved a detailed, in vivo examination of 
the brain microvasculature – which comprises endothelia – in response to AAV9-Glut1 administration. As 
emphasized in the paper and in our previous comments, the capillary network and, by inference, the endothelial 
cells were substantially rescued following such treatment. Additionally, we reiterate the results of our brain 
glucose uptake studies and CSF glucose measurements. These data constitute major components of our overall 
findings and, given the established role of brain endothelial Glut1 in the facilitated transport of glucose across 
the BBB, it is puzzling how each parameter would increase in AAV9-Glut1-treated mutants were it not for a 
concomitant increase in levels and/or function of the protein in these cells. It is true that glucose uptake, as 
assessed in fibroblasts, was not conducted using endothelial cells, but we believe that glucose measurements in 
CSF and brain are an even more physiologically relevant outcome when examining endothelial cell function post- 
treatment in the context of Glut1-DS. We trust this explanation serves to allay the concern of the reviewer. 
5.   Minor comments: 
(1)  Comment: “The methods indicate two routes of virus delivery, systemic and intra-cerebral injection. 
However, it has not been clarified which route has been used for each related experiment.” 
Response: We apologize for any confusion and note that the predominant choice of virus administration 
was systemic. ICV injection was only used to determine if this second mode of delivery also provided 
therapeutic benefit, which would indicate that such a route of administration also likely targets brain 
endothelial cells. Still, we address the comment by including a sentence (page 8) stating that, “Unless 
otherwise noted, subsequent results stem from systemically administered virus.” 
(2)  Comment: “Due to BBB, usually the local brain injection should yield higher viral expression. Please also 
provide immunohistochemistry images if there is no difference in Glut1 expression between the two 
injection routes.” 
Response: We agree that restricted, intrathecal delivery can result in higher levels of virally-derived 
transgenic constructs.  However, this would not be the case – as in our study – if titers were 
correspondingly lowered vis-à-vis systemic delivery. Accordingly, we did not observe a discernible 
difference between the two routes of delivery – a result we did not make explicit as we did not think it will 
alter the core message of our work.  Nevertheless, we include below for the benefit of the reviewer, 
representative images of the microvasculature following either ICV or systemic AAV9-Glut1 delivery. 
Additionally, we include in the Methods section a note (page 21) indicating the lower titer of the virus 
used for the ICV injections. 



































(3)  Comment: “Seems like no fluorescence being conjugated in the viral construct, so it is very difficult to 
evaluate the viral expression in the capillary endothelial cell as well as brain tissue.  It would be more 

























Fig. A. Immunohistochemistry of the brain 
microvasculature of 2-month old mice following AAV9- 
Glut1 delivery, at PND3, through the cerebral 
ventricles or bloodstream. Note equivalent expression 
of Glut1 protein in the two panels, as assessed by 
fluorescence intensity. Regions denoted by asterisks 
depict neuropil expressing the virally-derived Glut1 
protein. 
 
Response: We agree with the reviewer that inserting a tag into the construct would have enabled us to 
distinguish between virally-derived and endogenous Glut1 expression. However, such tags often interfere 
with transgene expression and/or function. Accordingly, we selected not to tag the transgene.  Still, based 
on independent studies (Foust, K.D. et al, 2009, Nat. Biotech. 27: 59-65; Foust, K.D. et al, 2010, Nat. 
Biotech. 28:271-274) and our own, we establish that AAV9 is capable of targeting brain endothelia as well 
as cells of the brain parenchyma (Supplementary Fig. 6A; also see Fig. A above). While our studies and 
those of Foust et al mostly involved the use of an AAV9-eGFP construct, we have no reason to believe that 
AAV9 carrying the Glut1 gene behaves any differently. Thus we are confident that both endothelia as well 
as astrocytes – the two likely sites of action of Glut1 – are targeted in our experiments. We further justify 
our use of lectin-stained vessels in quantifying the brain microvasculature based on an important result 
(Supplementary Fig. 1A) that we included in the original text.  This result indicated that lectin and Glut1 
invariably identify the same capillaries. This is true of all brain regions (thalamus, cortex and 
hippocampus) that we examined and applies equally to mice treated with AAV9-Glut1 (see Fig. B below). 
Thus we are reasonably certain that the quantification of the capillary network based on our lectin 
staining experiments is indeed an accurate reflection of the state of the Glut1-expressing, endothelial cell- 
derived brain microvasculature. We do hope this satisfactorily addresses the reviewer’s concern. 










25m Fig. B. Immunohistochemistry of the brain 
microvasculature of 2-month old mice treated with 
AAV9-Glut1 at PND3. Note that lectin stained 
structures are in perfect register with Glut1-positive 
vessels, justifying the use of lectin in quantifying the 
complexity of the brain capillary network. 
activity as author [sic] states, experiments should be done to indicate how effective the treatment [sic] to 
reduce seizures.” 
Response: The reviewer is absolutely correct.  Glut1-DS is indeed characterized by epileptic-like seizure 
activity, and this is true of our model mice. We apologize for omitting this analysis in the original text and 
now show (Supplementary Fig. 7I, J and accompanying text on page 11) that whereas seizures, as 
determined by abnormal EEG activity, persist in vehicle-treated animals, they are greatly mitigated in 
mutants treated with AAV9-Glut1. Owing to the extremely time-consuming nature of these studies, we 





The reviewer was generous with his/her comments noting our “results are clearly presented and [that] the conclusions 
are supported by the experimental data.” S/he goes on to indicate that “the manuscript is well-written and easy to 
understand.” Nevertheless, s/he requested two clarifications which we offer below. 
1.   Comment: “I find it surprising that no effect on the integrity of the BBB can be observed since the brain 
parenchyma obviously suffers from an energy deficient state. The author use fluorescently labelled 
macromolecules to reach this conclusion. This is also in contrast to a previous finding in the fish. Have the 
authors tested tracers of lower molecular weights to more carefully address the BBB integrity and can that 
explain the differences to previous results?” 
Response: The reviewer raises a pertinent point and we address his/her queries as follows. First, we did indeed 
note the difference in BBB integrity between our Glut1-DS model mice and the zebrafish model of the disease 
developed by Zheng and colleagues. Perhaps the most parsimonious way to explain the discrepancy is to 
emphasize the difference in the level of Glut1 knockdown in the two model organisms. Whereas the model 
mice are haploinsufficient and thus expected to express ~50% of the normal protein, the fish, resulting from a 
Glut1 antisense morpholino knockdown, express only ~10% of the protein. The far greater decline in Glut1 in 
the fish could well explain the more severe effects on the BBB in this model. We had alluded to this in the 
original Discussion section and once again draw the reviewer’s attention to this distinction between the two 
models.  Notwithstanding the differences in Glut1 levels in the two models and the varying ramifications they 
might have on BBB integrity, we resolved, as recommended by the reviewer, to further investigate the barrier in 
our mice. Accordingly, we substituted labeled IgG and albumin with a much smaller tracer – TMR-biocytin in 
new experiments. TMR-biocytin (~900 daltons) is at least two orders of magnitude smaller than either albumin 
or IgG. Consistent with our previous data, we found no evidence of a leaky BBB in Glut1-DS mice.  Indeed, there 
was no difference in staining patterns between wild-type and mutant brain tissue following administration of 
the tracer whereas copious fluorescence was detected in the parenchyma when the BBB was chemically 
disrupted with kainic acid. Our overall results, which now include the new data in Supplementary Fig. 3A, argue 
convincingly for a grossly intact BBB in Glut1-DS model mice. In future, we will extend our analysis by measuring 
the trans-endothelial resistance of mutant and wild-type brain endothelial cell monolayers as a means of 
confirming our current findings. 
2.   Comment: “Can the authors explain why there are very significant differences in CSF glucose concentrations 
between the mutant mice, mutant mice + AAV transducer and wt, probably reflecting differential endothelial 
uptake of blood glucose, and the PET data presented in Fig. 5a. The discrepancy is quite huge and needs to be 
explained.” 
Response: The reviewer makes an important observation noting an apparent discrepancy between the results of 
the PET experiments and those involving the measurements of CSF glucose.  However, in making the distinction, 
it is important to bear in mind that the PET images represent a snapshot in time (immediately after 
administration of the [18F] FDG) whereas the CSF glucose measurements denote steady state levels. While we 
believe that this is the most likely explanation for the perceived differences, we also note that in each 
experiment the AAV9-treated animal displayed evidence of greater glucose uptake than its vehicle-treated 
counterpart. In this respect, the results obtained from the two experiments are entirely consistent. We 
conclude by noting that additional experiments to examine the dynamics of glucose uptake by PET scans are 




We thank the reviewer for acknowledging the significance of our main result – that the brain microvasculature defects 
and Glut1 deficiency disease phenotype are indeed prevented/reversed following restitution of the Glut1 protein. Her 
main concern related to the significance of the 45kDa (astrocytic) Glut1 isoform. This was summarized in the initial 
comment below. We are grateful to the reviewer for allowing us the opportunity to respond to this as well as her other, 
secondary criticisms. 
1.   Comment: “A major concern this reviewer has with this manuscript is the failure to recognize the significance of 
the other Glut1 protein (45 KDa) that resides in all glia, which in this mouse model is also reduced by 50%. On 
Western blots of whole adult brain tissue it represents >65% of the total Glut1 protein (Vannucci, ref 47) that is 
detected and there is no indication as to whether in the repletion experiments, the Glut1 aav9 virus is 
repopulating the transporter deficient astrocytes. The blots as presented do not adequately resolve the proteins 
in the brain samples. 
Response: We apologize for any confusion with regard to the repletion of the astrocytic (45kDa) isoform of the 
protein, and do not wish to categorically state or imply in any fashion that our AAV9-Glut1 vector fails to restore 
this particular isoform to our mutant mice. On the contrary, the restoration is expected to be isoform-neutral, 
raising levels of the 55kDa as well as 45kDa species. In new experiments (Supplementary Fig. 6H), we show that 
this is indeed the case. Levels of each isoform, which are now adequately resolved on the gel, increase. We 
complement this new data with an acknowledgment (Discussion section – page 18) of the role of the astrocyte 
in the microvasculature defects identified. This is further reflected in a modified version of our model – Fig. 8 – 
in which the 45kDa isoform is now depicted on astrocytes, and references to reduced glycolytic flux in 
endothelia and/or astrocyte made in the text associated with the figure. We do hope the collective response 
adequately assuages the reviewer’s concerns. 
2.   Comment: “It seems obvious given the time table for neurogenesis [brain circuitry?] in the mouse is essentially 
complete by 4 weeks that adding back what would be a vital transporter for development 4 or 16 weeks after 
neurogenesis is completed would be without effect.” 
Response: The reviewer makes an interesting point, and while one might expect the restoration of a protein 
involved in brain maturation after the neuronal circuitry is normally established to be futile, we cite the 
intriguing example of another pediatric neurodevelopmental disorder – Rett syndrome.  This disease, which is 
caused by mutations in the MeCP2 protein shares certain features, notably 1) an absence of overt 
neurodegeneration and 2) microcephaly with Glut1-DS. Considering the profound effects of MeCP2 loss on 
brain function (selective loss of protein function in the mouse CNS is sufficient to cause a Rett syndrome-like 
phenotype), one might expect that restoring the protein past the normal window of brain maturation would also 
be without effect. Surprisingly, this is not the case (Guy, J et al, 2007, Science, 315:1143; Robinson, L et al, 2012, 
Brain, 135:2699). Repletion of MeCP2 at ~12 weeks, well after appearance of an overt phenotype was 
nevertheless highly effective in rescuing the disease phenotype.  Unfortunately, this does not appear to be the 
case in Glut1-DS – one reason we thought it best not to harbor any preconceived notions about the relationship 
between the maturation of the individual cells constituting brain circuits and the therapeutic window of 
opportunity in such a disease. 
3.   Comment: “In Figure 3 the authors describe the infection of patient fibroblasts with the Glut1 aav9 construct. A 
couple of questions arise 1) why are there two forms of the transporter and do they really represent a 45KDa 
and 55 KDa form of the transporter or is this an artifact of gel system. Running a microvessel sample as a control 
would address this question. 2) Do the control patient fibroblasts increase their transporter level if infected?” 
Response: The reviewer makes an astute observation relating to the two fibroblast-derived bands that were 
recognized by our Glut1 antibody. We intuitively labeled them 45kDa and 55kDa, as we would have done bands 







Fig. C. Western blot analysis of Glut1 isoforms in 
human fibroblasts and rodent brain tissue. 
blot in Fig. C), we find that these bands do not correlate to the two widely reported rodent endothelial and 
astrocytic Glut1 isoforms. We continue to detect two bands in the fibroblast samples, one of which is quite faint 
(arrowhead). However, neither band migrates at the sizes displayed by the Glut1 isoforms from the rodent 
brain.  We can only conclude that the Glut1 species detected in the human fibroblasts are processed 
(glycosylated?) in a novel manner.  Importantly this does not detract from the main message being 
communicated in the original Fig. 3a (now Fig. 3e), i.e., that transducing the fibroblasts with our Glut1 constructs 
increases the expression of the protein. Still, we thank the reviewer for her keen observation and have re- 
marked the bands in the figure with the simple label “Glut1.” We also note that control cells transfected with 
our Glut1 constructs do indeed exhibit evidence of increased (~50%, relative to sham-transfected) transporter 
based on uptake assays. However, since these studies were conducted on CHO cells, we chose not to include 
them in the manuscript. We hope this is construed by the reviewer as a reasonable decision. 
4.   Comment: “There appears to be no distinction as to whether the virus was presented by icv or through the facial 
vein therefore it would appear that the virus has complete access to the CNS by either route. Can the authors 
confirm this and demonstrate incorporation of the viral Glut 1 into astrocytes. 
Response: AAV9 when administered either systemically or ICV in neonatal mice is known to efficiently target CNS 
cells (Foust, K.D. et al, 2009, Nat. Biotech. 27: 59-65; Passini, M.A. et al, 2010, J. Clin. Invest. 120: 1253). 
Moreover, our immunohistochemistry experiments using AAV9-eGFP clearly indicate that this serotype is 
capable of infecting astrocytes (Supplementary Fig. 6A). We have no reason to believe that AAV9-Glut1 behaves 
any differently and do hope that in conjunction with our western blot data showing an increase in the 45kDa 
band in AAV9-Glut1 treated mice (Supplementary Fig. 6H) the immunohistochemistry result adequately 
convinces the reviewer of efficient transduction of the astrocytes by AAV9-Glut1. 
5.   Comment: “P10 – not transgenic” 
Response: We regret the misleading terminology and have changed this in the text (page 12) to “construct- 
derived.” 
6.   Comment: “P12- 'prevents release into the circulation' needs clarification.” 
Response: We have attempted to clarify the sentence by replacing it with the following statement: “Considering 
that the measurements were made in fasting animals, one possible explanation of this outcome is that systemic 
expression of virus predisposes the animals, when fasted, to hypoglycemia– a likely result of high expression of 
the Glut1 transgene in organs such as liver and muscle where it contributes to elevated glucose uptake thus 
lowering serum glucose concentrations.” 
7.   Comment: “A discussion of the similarities and differences between the current paper and that of Winkler et al 
should be expanded.” 
Response: We have now added to the Discussion section (page 17), speculating on the possibility that mouse 
strain-based differences might explain the different phenotypes reported by Winkler et al and us. This oft- 
overlooked factor can have a profound effect on disease phenotypes in model mice.  Accordingly, one possibility 
is that the mixed 129/SvJ-C57Bl/6J background used by Winkler and colleagues, in contrast to the pure 129SvJ 
strain we utilized, exacerbates BBB phenotypes in the former study. The mixed background in the Winkler et al 
study arose from the necessity of breeding the Glut1-DS model mice to an animal model of Alzheimer’s disease, 
which was generated on the C57Bl/6J strain background. We make reference to the different strain 
backgrounds utilized by the two groups in our revised text and do hope it adequately addresses the reviewer’s 
comment. 
8.   Comment: “Angiogenesis is but one component in the neural dysfunction caused by a lack of Glut1-see general 
comments. This requires Fig 8 to be revised or scraped [sic].” 
Response: We fully appreciate the reviewer’s comment (also see response to Comment #1) and have included 
new statements as well as a modified Fig. 8 acknowledging the important role that astrocytes might play in 
triggering the Glut1-DS disease phenotype. 
9.   Comment: “P16 the increase in 45 KDa Glut1 concentration is 5 fold between day14 and 28 whereas the 55 kDa 
Glut1 is at most 2 fold over the same period (ref 47). 
Response: We regret the error and have now altered the sentence (page 18) to reflect the precise findings in the 
article by Vannucci and Vannucci. 
10. Comment: “The resolution of 55 and 45 KDa could be significantly improved to resolve any differential 
contribution of the viral transporter to the glia and endothelial cell.” 
Response: We have now added the results of a second western blot experiment (Supplementary Fig. 6H) in 
which the bands are more clearly resolved and demonstrate an increase in both the 45kDa and 55kDa band in 
the AAV9-Glut1-treated mice. 
 
We do sincerely hope that the explanations provided in this letter, the results of our new experiments and the collective 
modifications to the text satisfactorily address the reviewers’ concerns. 
 
 
Reviewers' comments:  
 
Reviewer #1 (Remarks to the Author):  
 
The additional evidences as well as the thorough explanation that provided by the authors in this re-
submission has addressed the majority of my concerns. I would suggest to accept this manuscript.  
 
 
Reviewer #2 (Remarks to the Author):  
 
In the revised version of the manuscript the authors have provide novel data and responded well to 
the questions raised by me and the other reviewers. The minor typo on line 439 should be corrected 
and in FIg.3e the labeling of the lanes should be properly aligned. I have no further comments.  
 
 
Reviewer #3 (Remarks to the Author):  
 
This manuscript represents a resubmission of a manuscript entitled "Brain microvasculature defects 
and Glut1-deficiency syndrome averted by early repletion of the Glucose Transporter-1 protein"  
General comments  
The authors have addressed many of the reviewers’ comments but others remain unanswered. The 
most glaring is the failure of the authors to grasp the role of the endothelial cell to deliver glucose to 
the brain. The endothelial cells represent 2% of the cells in the brain, the other 98% is made up of 
glia and neurons which are inherently more active and the glucose that they require passes through 
the endothelial cells. Even in the mutants where the level of transport is reduced by 50% and CSF 
glucose is lowered and neurons and glia are effectively energy depleted they are still responsible 
transporting 25 X more glucose than they require to maintain endothelial cell metabolism. To 
accomplish this feat of energy supply, they are equipped with approximately 20-30 times the 
concentration of GLUT1 glucose transporters than the astrocytes. Thus the notion that endothelial cells 
are energy deficient as the underlying cause for the failure to undergo angiogenesis is not tenable 
despite the vigorous rebuttal to reviewer 1. The disparity in the levels of transporter could be 
immediately demonstrated if the western blot used for demonstrating the VEGFrs was re-probed for 
GLUT1. In part of that rebuttal the authors remark that both astrocytes and fibroblast show reduced 
metabolic activity. It is precisely this reduced metabolic capacity in astrocytes and pericytes due to 
their lower [GLUT1] and lower ambient interstitial glucose that is a more likely the cause of impaired 
angiogenesis. The authors report a reduced Vegf2r in the endothelial cells but should note that 
astrocytes are an important source of VEGF and are responsible for providing vascular scaffolding and 
endothelial cell survival. Note Figure 8 should be modified to indicate the disparity in GLUT1 between 
endothelial cells and astrocytes.  
This reviewer also found the response to reviewer 2 comment’ regarding the disparity between the 
reduction in transport and PET unsatisfactory. What should be noted is that PET is a measure of 
glucose metabolism in the astrocytes and neurons not transport and what is observed is the overall 
level of metabolism is reduced only moderately because the animals were anesthetized and 
consequently the energy requirement could still be fulfilled by the lower ambient glucose.  
Specific Comments  
Abstract  
The cognitive dysfunction is undoubtedly due insufficient glucose to enable neuronal function, which 
the authors have published on extensively.  
L.278 this should point out PET changes is in anesthetized animals and CSF glucose reflect free 
moving animals.  
L445-458 needs to be reconsidered and other references to reduced glycolysis that is very unlikely 
based on discussion above and as pointed by reviewer 1 was not measured.  
The western blots presented in Figure 3 are really misleading as there is no distinction made between 
45 KDa astrocyte glucose transporter and the much lighter 55 KDa band which is the endothelial cell 
GLUT1 and the major focus of the study. Putting the resolution of the two in the supplement and not 
referring at all to the significance of the two bands is clearly inappropriate. As suggested above re-
probe the Vegfr blot to illustrate the relative changes in both in the vessels and vessel free 
membranes along with a whole brain fraction where they are resolved and the relative concentrations 






1.   Comment: “The additional evidence as well as the thorough explanation that [was] provided by the authors in 
this re-submission has addressed the majority of my concerns. I would suggest accepting this manuscript.” 
Response: We are pleased that we were able to satisfactorily address the reviewer’s concerns and delighted that 





1.   Comment: “In the revised version of the manuscript the authors have provided novel data and responded well 
to the questions raised by me and the other reviewers. The minor typo on line 439 should be corrected and in 
Fig. 3e the labeling of the lanes should be properly aligned.  I have no further comments.” 
Response: We are grateful for having had the opportunity to respond to the Reviewer and glad that s/he too 




We appreciate the reviewer’s continued concerns and attempt, to the best of our ability, to address them in this second 
revision. 
1.   Comment: The reviewer objects to speculations in the Discussion section that the angiogenesis defects we 
observe might stem from defects in endothelial cells, suggesting instead that reduced metabolic activity of 
astrocytes is a “more likely” trigger. 
Response: We appreciate the reviewer’s viewpoint and begin by reiterating statements in the Discussion section 
of the manuscript explicitly acknowledging a possible role for astrocytes and/or pericytes in precipitating the 
microvasculature defects that were observed (page 18).  These, we noted, could have been triggered in the 
endothelial cells in a non-cell autonomous manner by perturbations originating in astrocytes or pericytes. 
However, given our current, somewhat limited understanding of angiogenesis defects in Glut1 deficiency, the 
exact contribution of various cell-types (endothelial cells, pericytes, astroctyes) to the abnormalities and the 
precise mechanisms operating within the cell-types to arrest capillary development can only be speculated on. 
Indeed, as acknowledged by the reviewer, the role of astrocytes in triggering the arrest of angiogenesis is at best 
“more likely” rather than absolutely certain.  To unequivocally state that one cell-type or another is at the root 
of the microvasculature defects, notwithstanding Glut1 expression differences between them, will require 
considerable additional work that is simply beyond the scope of the current article which is primarily a proof-of- 
concept study of the mitigating effects of restoring Glut1 in Glut1 DS. We nevertheless make an earnest 
attempt to address the reviewer’s comment and do so in two ways. First, we re-modify Fig. 8 by adding a note 
to the legend acknowledging the much greater expression of Glut1 in endothelial cells relative to astrocytes. 
The endothelial cells are shown in the cartoon to have more transporters than the astrocytes, but given the 
obvious limitations of depicting them using this medium, the relative levels of Glut1 in the two cells could be 
misconstrued. We hope the note in the legend clarifies and adequately addresses this shortcoming. Secondly, 
as suggested, we now include blots of Glut1 in the capillaries and brain parenchyma fractions illustrating the 
relative levels of the protein in endothelial cells vs. neuropil.   This constitutes part of Fig. 3b – the blot in which 
we examined Vegfr2 levels - and depicts a low as well as high exposure time.  The new data confirms earlier 
findings that endothelial cells express much higher levels of Glut1 than does nervous tissue. However, it does 
not allow one to unequivocally infer if the protein, particularly in mutant endothelial cells, is properly localized 
to the membrane and thus of functional consequence.  Mis-localization of Glut1 from the luminal to cytoplasmic 



































































































2.   Comment: “The authors report a reduced Vegf2r in the endothelial cells but should note that astrocytes are an 
important source of VEGF and are responsible for providing vascular scaffolding and endothelial cell survival.” 
Response: We thank the reviewer for this important information and examined VEGF expression levels in the 
neuropil of Glut1 DS mutants and wild-type controls at two different time points – PND14 and PND60. At 
neither point in time did levels of VEGF change significantly in the mutants, suggesting that perturbations in 
concentrations of this ligand are unlikely to have a major/direct effect on angiogenesis arrest in Glut1 DS 
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3.   Comment: “The cognitive dysfunction is undoubtedly due insufficient glucose to enable neuronal function, 
which the authors have published on extensively.” 
Response: We regret the confusion with regard to this statement. The sentence refers specifically to the dearth 
of information associated with possible (now conclusive) brain pathology underlying Glut1 DS and how such 
pathology might trigger cognitive dysfunction. 
4.   Comment: “L278 this should point out PET changes is in anesthetized animals and CSF glucose reflect free 
moving animals.” 
Response: As recommended we now make reference to the anesthetized state of the animals undergoing PET 
scans (page 10).  We also clearly state in the revised text that CSF glucose measurements reflect levels in freely 
moving animals (page 21) 
5.   Comment: “L445-458 needs to be reconsidered and other references to reduced glycolysis that is very unlikely 
based on discussion above and as pointed by reviewer 1 was not measured.” 
Response: As alluded to in our response to Comment #1, we believe, given our current understanding of the link 
between Glut1 and angiogenesis, that it is impossible to unequivocally state which cell type(s) is/are responsible 
for the defects.  Accordingly, we respectfully maintain the possibility that the microvasculature defects may 
arise in astrocytes and/or endothelial cells. 
6.   Comment: The reviewer objects to the placement of a blot depicting the 45kDa and 55kDa Glut1 bands in the 
Supplemental Information. 
Response: As suggested, we have moved the above referenced blot from the Supplemental Information to the 
main text where it now constitutes Fig. 4d. Moreover, we draw the reviewer’s attention to a statement in the 
manuscript indicating an increase in both the 45kDa and 55kDa bands following systemic Glut1 repletion (page 
9). 
7.   Comment: The reviewer suggests re-probing the Vegfr2 blot in “Figure 3” for Glut1. 
Response: As suggested, and as referred to in our response to Comment #1, we now show two exposures of the 
Vegfr2 blot (Fig. 4b) re-probed for Glut1. Corresponding reference to the new data is made in the relevant 
figure legend. 
 
We thank Reviewer 3 for his/her insightful comments and do hope the explanations above and the revisions to the text 
satisfactorily address all remaining concerns about our article. 
 
 
REVIEWERS' COMMENTS:  
 
Reviewer #3 (Remarks to the Author):  
 
I would like to state at the outset that I would like to see this paper published as I feel it make an 
important contribution to the field and the inconsistencies that are being pointed do not take away 
from the overall strength of the paper but do confuse the potential interpretations. However, this 
represents the third review of this manuscript and as such I am going to confine myself to the salient 
points of my previous critics that have still not been addressed.  
The authors appear to have a reluctance to acknowledge that there are two forms of the GLUT1 
glucose transporter in the CNS. The endothelial cells express the 55 KDa form and the astrocytes, 
microglia,and pericytes express the 45Kda. In terms of cellular concentration the endothelial cells 
express a greater level than than the other cells (10-30fold) as illustrated in amended Figure 3 but in 
terms of total CNS GLUT1, the 45 Kda isoform is significantly more abundant than the 55 KDa isoform 
as illustrated in Figure 4. The same applies for the mRNA determination is made its origin cannot be 
distinguished between that the respective cells without fractionation. Similarly, when repletion occurs 
both the 45 and 55 KDa isoforms are repleated. The problem then arises with the western blots and 
mRNA in Figure 4 in that what is illustrated and quantified in the upper blot is primarily the astrocytic 
45 KDa band which is not stated in the manuscript and consequently misleading. The mRNA 
determination is clearly the total GLUT1 mRNA of which most would be derived from the cells 
expressing the 45 KDa isoform. All of this confusion could be alleviated by showing the wild type 
whole brain expression of both 55 and 45 KDa on the bottom blot with the same resolution and is not 
apparent in the top blot and consequently misleading. Indeed it would then be possible to determine if 
the virus differentially infected the endothelial cells, astrocytes, or perhaps neurons.  
Having acknowledged the number of transporters in the endothelial cells is significantly higher than 
astrocytes (see above and p.40)and that in the mutant while CSF levels are glucose is lower than wild, 
the endothelial transportes in the mutant are still working albeit at half capacity. This reviewer has 
repeated suggested that the endothelial cells cannot be glucose deprived as the endothelial cells would 
use but a tiny fraction of the glucose that passes through them which has not be addressed. Using 
astrocytes as a model for endothelial cells having clearly demonstrated that they have far fewer 
transporters as a model is clearly flawed Showing that the astrocytes are compromised is important as 
this would limit angiogenisis and reduce potential astrocyte release of lactate but cannot be equated to 
metabolism in endothelial cells. Equally a pfk mutation would impair ATP production - reducing level of 
transporter by a factor of two would have no effect on endothelial cell metabolism as the cellular levels 
of glucose would still saturate hexokinase and without any further impairment would metabolize 
normally.  
The authors suggest that the reduced expression of vegfr in the mutant mice may underlie the 
reduced angiogenisis but it would be important to demonstrate that it expression is restored in the 





We once again thank the reviewer for her time and effort.  Her comments and our detailed responses appear below. 
1.   Comment: The reviewer claims that there is “a reluctance to acknowledge that there are two forms of the 
GLUT1 glucose transporter in the CNS” and that it is unclear which form is ultimately being restored. 
Response: We regret the reviewer’s perception, noting that the purpose of the work was not to focus on any 
particular Glut1 isoform and that the repletion strategy we chose was never meant to enhance levels of one 
isoform at the expense of the other.  This was made abundantly evident by 1) Stating (see Results section) that 
regulatory elements of the ubiquitously expressed chicken -actin gene were used to drive the expression of the 
Glut1 construct in our AAV9 vector and 2) That the systemically administered AAV9 vector targets endothelial 
cells (ECs) and astrocytes – the sources of the 55kDa and 45kDa isoforms respectively (Suppl. Fig. 6A).  Still, to 
address the reviewer’s concern, we now indicate in the legend to Fig. 4 that quantification of Glut1 in the 
various animal cohorts takes into account both astrocyte as well as endothelial cell-derived protein. 
Unfortunately, the related western blots will not, as suggested by the reviewer, allow one to gauge relative 
transduction in individual subsets (astrocytes and neurons) of cells of the brain parenchyma. We hope the new 
clarification here and in the text addresses the reviewer’s comment. 
2.   Comment: The reviewer claims that given the concentrations of Glut1 in ECs, haploinsufficiency of the protein is 
simply incapable of reducing glucose concentrations within them to affect their metabolism. Additionally, she 
comments that “using astrocytes as a model for endothelial cells having clearly demonstrated that they have far 
fewer transporters as a model is clearly flawed.” 
Response: We appreciate the reviewer’s remarks and respond by 1) Reiterating a possibility we noted in our 
previous rebuttal and 2) Highlighting established facts about EC sub-types. First, while it is true that ECs have 
high concentrations of Glut1, this does not automatically mean that they are all appropriately localized, 
particularly in disease conditions, in the luminal and abluminal membranes to effect glucose transport.  It is well- 
established that even in WT endothelial cells, Glut1 protein is not all inserted into the membrane, but instead 
distributed in a ratio of 12% (luminal): 40% (cytoplasmic): 48% (abluminal) in these three cellular domains 
(Farrell and Pardridge, 1991, PNAS, 88:5779) and, furthermore, that such distribution is subject to all manner of 
physiological perturbations including insulin signaling and cell stress (Widnell, C.C. et al, 1990, FASEB J. 4:1634; 
Palmada, M., et al, 2006, Diabetes, 55:421; Ramlal, T. et al, 1988, Biochem Biophys Res Commun, 157:1329). 
Such perturbations could very well operate in Glut1 DS, further depleting membrane-bound Glut1 beyond the 
expected 50% that results from the haploinsufficiency. The combined effects would allow for the very real 
possibility that haploinsufficiency disproportionately affects glycolytic flux not just in brain parenchyma cells but 
also in ECs. A second factor that must be considered when describing metabolism of brain ECs is to note that 
these cells are not all homogeneous, particularly during microvasculature expansion. Rather, they consist of at 
least three sub-types – tip cells, stalk cells and phalanx cells (Potente, M. et al, 2011, Cell, 146:873). Phalanx 
cells are mature, quiescent and fully perfused with blood, serving primarily as conduits to transport blood 
nutrients to the brain parenchyma and clear away by-products of neuronal/astrocyte metabolism. Admittedly, 
these are cells unlikely to suffer physiologically meaningful changes in glycolytic flux to alter their metabolism in 
Glut1 DS, assuming that the remaining transporters continue to be properly localized to the luminal and 
abluminal membranes.  In contrast, tip cells which develop filopodia and lamellipodia to form new vessel 
sprouts and an expanded capillary network into avascular tissue, operate in a quite different microenvironment 
and, accordingly, could be expected to respond differently to low Glut1.  These cells exist in a non-perfused state 
and are thus exposed to levels of glucose that are close to an order of magnitude lower than those seen by 
phalanx cells (Abi-Saab, W.M. et al, 2002, J. Cereb Blood Flow Metab, 22:271). If the model of Barros et al 
(Barros, L.F. et al, 2007, Glia, 55:1222) wherein a 50% loss in Glut1 results in a 90% drop in brain glucose is valid, 
then in Glut1 DS the endothelial tip cells would be exposed to even lower levels of glucose.  It would then not be 
surprising for glycolytic flux in such tip cells, dually burdened with half as much Glut1 and profoundly low 
environmental glucose, to be directly affected thus disrupting angiogenesis. This was implicit in our discussion 
of the results of our findings and it was expected that the expert reviewer would have considered it. To avoid 
doing so is to ignore established research findings pertinent to the speculation in our discussion. Still, in 
deference to the reviewer’s comments, we have extensively modified the discussion making certain not to refer 
to glucose-deprived ECs while emphasizing the role of the tip cells in microvasculature formation. Finally, we 
note that one is not equating metabolism in astrocytes to metabolism in ECs. Rather, we extrapolate relative 
metabolism in mutant versus WT astrocytes to relative metabolism in mutant versus WT ECs.  If one assumes 
that the percent decrease in Glut1 is equivalent in the two types of cells in Glut1 DS, then we believe that the 
extrapolation is justified.  We hope our aggregate response allays, once and for all, this remaining reviewer’s 
concerns. 
3.   Comment: “The authors suggest that the reduced expression of vegfr2 in the mutant mice may underlie the 
reduced angiogenesis but it would be important to demonstrate that it [sic] expression is restored in the mice 
with the repleated [sic] GLUT1.” 
Response: The Vegfr2 data was not an original concern of the reviewer’s and was included in response to a 
comment from an independent reviewer (Reviewer #1). That reviewer appeared fully satisfied with our 
response. We hope the matter rests there, particularly (and as recognized by the two other reviewers who now 
find our manuscript eminently suitable for publication) as it is decidedly peripheral to the crux of the current 
article which is to highlight the feasibility and promise of gene therapy in Glut1 DS. We hope the reviewer 
agrees and is further assuaged by our fullest intent to address the link between Vegfr2 and Glut1 in future 
studies. 
 
We reiterate our sincere gratitude to the reviewer and trust that the explanations provided above and in the main text 
fully address all her comments. 
 
 
